Kuhlow John, who is VP/Controller at JB Hunt Transport Services, bought 1,284 shares at $81.34 on Nov. 25, 2014. Following this transaction, the VP/Controller owned 4,360 shares meaning that the stake was boosted by 41.74% with the 1,284-share transaction.

The shares most recently traded at $81.46, up $0.12, or 0.15% since the insider transaction. Historical insider transactions for JB Hunt Transport Services go as follows:

4-Week # shares bought: 7,800

4-Week # shares sold: 115,802

12-Week # shares bought: 7,800

12-Week # shares sold: 220,302

24-Week # shares bought: 7,800

24-Week # shares sold: 268,200

The average volume for JB Hunt Transport Services has been 982,400 shares per day over the past 30 days. JB Hunt Transport Services has a market cap of $9.5 billion and is part of the services sector and transportation industry. Shares are up 5.87% year-to-date as of the close of trading on Monday.

J.B. Hunt Transport Services, Inc., together with its subsidiaries, provides transportation and delivery services in the continental United States, Canada, and Mexico. The stock currently has a dividend yield of 0.98%. The company has a P/E ratio of 27.2. Currently, there are 9 analysts who rate JB Hunt Transport Services a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Quant Ratings rates JB Hunt Transport Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, increase in stock price during the past year and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full JB Hunt Transport Services Ratings Report from TheStreet Quant Ratings now.

Schamroth Michael, who is Director at BioSpecifics Technologies Corporation, sold 4,499 shares at $39.36 on Nov. 25, 2014. Following this transaction, the Director owned 30,000 shares meaning that the stake was reduced by 13.04% with the 4,499-share transaction.

The shares most recently traded at $26.12, down $13.24, or 50.67% since the insider transaction. Historical insider transactions for BioSpecifics Technologies Corporation go as follows:

4-Week # shares sold: 50,501

12-Week # shares sold: 50,501

24-Week # shares sold: 50,501

The average volume for BioSpecifics Technologies Corporation has been 29,500 shares per day over the past 30 days. BioSpecifics Technologies Corporation has a market cap of $161.0 million and is part of the health care sector and drugs industry. Shares are up 17.26% year-to-date as of the close of trading on Friday.

BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. The company has a P/E ratio of 33.4.

Federighi Craig, who is Senior Vice President at Apple, sold 81,543 shares at $116.81 on Nov. 25, 2014. Following this transaction, the Senior Vice President owned 237,049 shares meaning that the stake was reduced by 25.59% with the 81,543-share transaction.

The shares most recently traded at $117.60, up $0.79, or 0.67% since the insider transaction. Historical insider transactions for Apple go as follows:

4-Week # shares sold: 7,610

12-Week # shares sold: 26,000

24-Week # shares sold: 34,582

The average volume for Apple has been 58.8 million shares per day over the past 30 days. Apple has a market cap of $683.1 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 48.01% year-to-date as of the close of trading on Monday.

Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications. The stock currently has a dividend yield of 1.61%. The company has a P/E ratio of 18.1. Currently, there are 26 analysts who rate Apple a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Quant Ratings rates Apple as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Apple Ratings Report from TheStreet Quant Ratings now.